(1) Background: Artificial intelligence (AI) has flourished in recent years. More specifically, generative AI has had broad applications in many disciplines. While mental illness is on the rise, AI has proven valuable in aiding the diagnosis and treatment of mental disorders. However, there is little to no research about precisely how much interest there is in AI technology. (2) Methods: We performed a Google Trends search for “AI and mental health” and compared relative search volume (RSV) indices of “AI”, “AI and Depression”, and “AI and anxiety”. This time series study employed Box–Jenkins time series modeling to forecast long-term interest through the end of 2024. (3) Results: Within the United States, AI interest steadily increased throughout 2023, with some anomalies due to media reporting. Through predictive models, we found that this trend is predicted to increase 114% through the end of the year 2024, with public interest in AI applications being on the rise. (4) Conclusions: According to our study, we found that the awareness of AI has drastically increased throughout 2023, especially in mental health. This demonstrates increasing public awareness of mental health and AI, making advocacy and education about AI technology of paramount importance.

Background: Cardiac rehabilitation (CR) is an evidence‐based, guideline‐recommended intervention for patients recovering from a cardiac event, surgery or procedure that improves morbidity, mortality, and functional status. CR is traditionally provided in‐center, which limits access and engagement, most notably among underrepresented racial and ethnic groups due to barriers including cost, scheduling, and transportation access. This study is designed to evaluate the Corrie Hybrid CR, a technology‐based, multicomponent health equity‐focused intervention as an alternative to traditional in‐center CR among patients recovering from a cardiac event, surgery, or procedure compared with usual care alone. Methods: The mTECH‐Rehab (Impact of a Mobile Technology Enabled Corrie CR Program) trial will randomize 200 patients who either have a diagnosis of type 1 myocardial infarction or who undergo coronary artery bypass grafting surgery, percutaneous coronary intervention, heart valve repair, or replacement presenting to 4 hospitals in a large academic health system in Maryland, United States, to the Corrie Hybrid CR program combined with usual care CR (intervention group) or usual care CR alone (control group) in a parallel arm, randomized controlled trial. The Corrie Hybrid CR program leverages 5 components: (1) a patient‐facing mobile application that encourages behavior change, patient empowerment, and engagement with guideline‐directed therapy; (2) Food and Drug Administration‐approved smart devices that collect health metrics; (3) 2 upfront in‐center CR sessions to facilitate personalization, self‐efficacy, and evaluation for the safety of home exercise, followed by a combination of in‐center and home‐based sessions per participant preference; (4) a clinician dashboard to track health data; and (5) weekly virtual coaching sessions delivered over 12 weeks for education, encouragement, and risk factor modification. The primary outcome is the mean difference between the intervention versus control groups in distance walked on the 6‐minute walk test (ie, functional capacity) at 12 weeks post randomization. Key secondary and exploratory outcomes include improvement in a composite cardiovascular health metric, CR engagement, quality of life, health factors (including low‐density lipoprotein‐cholesterol, hemoglobin A1c, weight, diet, smoking cessation, blood pressure), and psychosocial factors. Approval for the study was granted by the local institutional review board. Results of the trial will be published once data collection and analysis have been completed. Conclusions: The Corrie Hybrid CR program has the potential to improve functional status, cardiovascular health, and CR engagement and advance equity in access to cardiac rehabilitation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05238103.